Figure 1
Figure 1. Maturation of monocyte-derived DCs with TLR agonists results in differential surface expression of DC maturation markers. Monocyte-derived DCs were activated with TLR4 and/or TLR7/8 agonists or with a defined mixture of cytokines (IL1β, TNFα, IL6, and PGE2) known to efficiently promote maturation. (A) Percentage of DCs demonstrating surface expression of all of the CD83/CD80/CD86 molecules within the FSC/SSC DC gate. Bars represent the means of 4 donors ± SEM. (B) Representative plots of the differential surface expression of CD80 and CD86 within the CD83low/neg DC population. (C) Percentage of DCs displaying CD80 or CD86 within the CD83Hi DC gate (top panel) or the CD83low/neg gate (bottom panel) from 3 donors (a, b, and c). **Statistical significance with P values shown.

Maturation of monocyte-derived DCs with TLR agonists results in differential surface expression of DC maturation markers. Monocyte-derived DCs were activated with TLR4 and/or TLR7/8 agonists or with a defined mixture of cytokines (IL1β, TNFα, IL6, and PGE2) known to efficiently promote maturation. (A) Percentage of DCs demonstrating surface expression of all of the CD83/CD80/CD86 molecules within the FSC/SSC DC gate. Bars represent the means of 4 donors ± SEM. (B) Representative plots of the differential surface expression of CD80 and CD86 within the CD83low/neg DC population. (C) Percentage of DCs displaying CD80 or CD86 within the CD83Hi DC gate (top panel) or the CD83low/neg gate (bottom panel) from 3 donors (a, b, and c). **Statistical significance with P values shown.

Close Modal

or Create an Account

Close Modal
Close Modal